Stabilization of activation induced cytidine deaminase by bortezomib does not confer increased drug target mutation frequency

Leuk Lymphoma. 2014 Jan;55(1):220-2. doi: 10.3109/10428194.2013.797575. Epub 2013 Jun 4.
No abstract available

Publication types

  • Letter

MeSH terms

  • Boronic Acids / pharmacology*
  • Bortezomib
  • Burkitt Lymphoma / enzymology
  • Burkitt Lymphoma / genetics
  • Cell Line, Tumor
  • Cytidine Deaminase / chemistry
  • Cytidine Deaminase / genetics*
  • Cytidine Deaminase / metabolism*
  • Drug Resistance, Neoplasm / genetics
  • Enzyme Activation / drug effects
  • Humans
  • Inhibitory Concentration 50
  • Mutation / drug effects*
  • Mutation Rate
  • Pyrazines / pharmacology*

Substances

  • Boronic Acids
  • Pyrazines
  • Bortezomib
  • Cytidine Deaminase